Sirtex Collaborates With MIM Software for Treatment of Hepatic Tumors

February 12, 2020—Sirtex Medical announced a collaboration with MIM Software Inc. Sirtex is a manufacturer of targeted liver cancer therapies, including the SIR-Spheres yttrium-90 (Y-90) resin microspheres. MIM Software focuses on imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging, and cardiac imaging.

Under the agreement, Sirtex will offer the MIM SurePlan LiverY90 software alongside its SIR-Spheres Y-90 microspheres to improve treatment precision for patients with hepatic tumors in the United States, Europe, and other global markets.

According to the company, MIM SurePlan LiverY90 provides timesaving tools and posttreatment dosimetry for interventional radiologists and nuclear medicine physicians treating hepatic tumors with SIR-Spheres. The software allows physicians to quickly calculate the dose delivered by the microspheres to improve treatment decisions and patient care. The technology also incorporates CT, positron emission tomography, single-photon emission CT, and MRI scans simultaneously to deliver results on spheres deposition, coverage, and absorbed dose, allowing physicians to make informed decisions faster about the next steps.

In the United States, SIR-Spheres Y-90 resin microspheres received FDA premarket approval and are indicated for the treatment of nonresectable metastatic liver tumors from primary colorectal cancer in combination with intrahepatic artery chemotherapy using floxuridine. SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumors in Australia, the European Union, Argentina, Brazil, Canada and several countries in Asia, such as India and Singapore.